Literature DB >> 1698946

Alz-50 recognizes a phosphorylated epitope of tau protein.

K Uéda1, E Masliah, T Saitoh, S L Bakalis, H Scoble, K S Kosik.   

Abstract

Alz-50 is a monoclonal antibody that detects antigens enriched in the brain tissue of Alzheimer's disease (AD) patients. Although Alz-50 recognizes tau, an identified integral constituent of the AD paired helical filament (PHF), the exact nature of the antigenic site is unknown. An immunoblot analysis demonstrated that the antigenic sites to Alz-50 are diminished by acid phosphatase treatment. Consistent with this finding, Alz-50 antigens were more concentrated in brain homogenates prepared with phosphatase inhibitors. The epitope in tau with which Alz-50 reacts is located in the carboxy terminus within a 14-amino acid region from just beyond the microtubule-binding repeats to the carboxy terminus. An isolated carboxy-terminal chymotryptic peptide from bovine brain tau reactive with Alz-50 was analyzed by fast-atom-bombardment mass spectroscopy (FAB-MS) and was found to be present as both a monophosphopeptide and a nonphosphorylated peptide. The immunohistological analysis has demonstrated that Alz-50 staining of neurofibrillary tangles (NFTs) is sensitive to acid phosphatase but not to alkaline phosphatase. Furthermore, Alz-50 staining of NFTs was effectively adsorbed by a high concentration of phosphoserine but not by serine or phosphothreonine. These results strongly suggest that Alz-50 recognizes a phosphorylated epitope in the carboxy terminus of tau which has not been previously detected by using alkaline phosphatase. The strong Alz-50 staining in AD samples may represent another association between a phosphorylation state and neurofibrillary lesions. As a marker of the inchoate tangle-bearing neuron, the characterization of the Alz-50 epitope in tau offers a partial molecular basis for the modifications that contribute to the assembly of PHFs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698946      PMCID: PMC6570176     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  17 in total

1.  Immunocytochemistry of neurofibrillary tangles with antibodies to subregions of tau protein: identification of hidden and cleaved tau epitopes and a new phosphorylation site.

Authors:  D W Dickson; H Ksiezak-Reding; W K Liu; P Davies; A Crowe; S H Yen
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

2.  Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau.

Authors:  D N Drechsel; A A Hyman; M H Cobb; M W Kirschner
Journal:  Mol Biol Cell       Date:  1992-10       Impact factor: 4.138

3.  The N terminal region of human tau is present in Alzheimer's disease protein A68 and is incorporated into paired helical filaments.

Authors:  A Crowe; H Ksiezak-Reding; W K Liu; D W Dickson; S H Yen
Journal:  Am J Pathol       Date:  1991-12       Impact factor: 4.307

Review 4.  The molecular significance of amyloid beta-peptide for Alzheimer's disease.

Authors:  C Haass
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

Review 5.  Probing modifications of the neuronal cytoskeleton.

Authors:  L C Doering
Journal:  Mol Neurobiol       Date:  1993 Fall-Winter       Impact factor: 5.590

6.  Brain transplants of cells expressing the carboxyl-terminal fragment of the Alzheimer amyloid protein precursor cause specific neuropathology in vivo.

Authors:  R L Neve; A Kammesheidt; C F Hohmann
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

7.  A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice.

Authors:  Varsha Shukla; Ya-Li Zheng; Santosh K Mishra; Niranjana D Amin; Joseph Steiner; Philip Grant; Sashi Kesavapany; Harish C Pant
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

8.  A68 proteins in Alzheimer's disease are composed of several tau isoforms in a phosphorylated state which affects their electrophoretic mobilities.

Authors:  J P Brion; D P Hanger; A M Couck; B H Anderton
Journal:  Biochem J       Date:  1991-11-01       Impact factor: 3.857

9.  A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease.

Authors:  K Hensley; J M Carney; M P Mattson; M Aksenova; M Harris; J F Wu; R A Floyd; D A Butterfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

10.  Immunohistochemical and histopathologic correlates of Alzheimer's disease-associated Alz-50 immunoreactivity quantified in homogenates of cerebral tissue.

Authors:  S M de la Monte; R A Spratt; J Chong; H A Ghanbari; J R Wands
Journal:  Am J Pathol       Date:  1992-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.